This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stowers, A. W.
Right arrow Articles by Miller, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stowers, A. W.
Right arrow Articles by Miller, L. H.

 Previous Article  |  Next Article 

Infection and Immunity, March 2001, p. 1536-1546, Vol. 69, No. 3
0019-9567/01/$04.00+0   DOI: 10.1128/IAI.69.3.1536-1546.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Efficacy of Two Alternate Vaccines Based on Plasmodium falciparum Merozoite Surface Protein 1 in an Aotus Challenge Trial

Anthony W. Stowers,1,* Vittoria Cioce,2 Richard L. Shimp,1 Mark Lawson,1 George Hui,3 Olga Muratova,1 David C. Kaslow,1,dagger Robin Robinson,2 Carole A. Long,1 and Louis H. Miller1

Malaria Vaccine Development Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health,1 and Novavax, Inc.,2 Rockville, Maryland, and Department of Tropical Medicine and Medical Microbiology, University of Hawaii, Honolulu, Hawaii3

Received 13 September 2000/Returned for modification 20 November 2000/Accepted 1 December 2000

In an attempt to produce a more defined, clinical-grade version of a vaccine based on Plasmodium falciparum merozoite surface protein 1 (MSP1), we evaluated the efficacy of two recombinant forms of MSP1 in an Aotus nancymai challenge model system. One recombinant vaccine, bvMSP142, based on the 42-kDa C-terminal portion of MSP1, was expressed as a secreted protein in baculovirus-infected insect cells. A highly pure baculovirus product could be reproducibly expressed and purified at yields in excess of 8 mg of pure protein per liter of culture. This protein, when tested for efficacy in the Aotus challenge model, gave significant protection, with only one of seven monkeys requiring treatment for uncontrolled parasitemia after challenge with P. falciparum. The second recombinant protein, P30P2MSP119, has been used in previous studies and is based on the smaller, C-terminal 19-kDa portion of MSP1 expressed in Saccharomyces cerevisiae. Substantial changes were made in its production process to optimize expression. The optimum form of this vaccine antigen (as judged by in vitro and in vivo indicators) was then evaluated, along with bvMSP142, for efficacy in the A. nancymai system. The new formulation of P30P3MSP119 performed significantly worse than bvMSP142 and appeared to be less efficacious than we have found in the past, with four of seven monkeys in the vaccinated group requiring treatment for uncontrolled parasitemia. With both antigens, protection was seen only when high antibody levels were obtained by formulation of the vaccines in Freund's adjuvant. Vaccine formulation in an alternate adjuvant, MF59, resulted in significantly lower antibody titers and no protection.

* Corresponding author. Mailing address: Malaria Vaccine Development Unit, LPD/NIAID/NIH, Twinbrook II Room 103, 12441 Parklawn Dr., Rockville, MD 20852. Phone: (301) 435-2968. Fax: (301) 435-6725. E-mail: astowers{at}niaid.nih.gov.

dagger Present address: Viral and Vaccine Research, Merck Research Laboratories, West Point, PA 19486.

Infection and Immunity, March 2001, p. 1536-1546, Vol. 69, No. 3
0019-9567/01/$04.00+0   DOI: 10.1128/IAI.69.3.1536-1546.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Malhotra, I., Wamachi, A. N., Mungai, P. L., Mzungu, E., Koech, D., Muchiri, E., Moormann, A. M., King, C. L. (2008). Fine Specificity of Neonatal Lymphocytes to an Abundant Malaria Blood-Stage Antigen: Epitope Mapping of Plasmodium falciparum MSP133. J. Immunol. 180: 3383-3390 [Abstract] [Full Text]  
  • Huaman, M. C., Martin, L. B., Malkin, E., Narum, D. L., Miller, L. H., Mahanty, S., Long, C. A. (2008). Ex Vivo Cytokine and Memory T Cell Responses to the 42-kDa Fragment of Plasmodium falciparum Merozoite Surface Protein-1 in Vaccinated Volunteers. J. Immunol. 180: 1451-1461 [Abstract] [Full Text]  
  • Faber, B. W., Remarque, E. J., Morgan, W. D., Kocken, C. H. M., Holder, A. A., Thomas, A. W. (2007). Malaria Vaccine-Related Benefits of a Single Protein Comprising Plasmodium falciparum Apical Membrane Antigen 1 Domains I and II Fused to a Modified Form of the 19-Kilodalton C-Terminal Fragment of Merozoite Surface Protein 1. Infect. Immun. 75: 5947-5955 [Abstract] [Full Text]  
  • Kumar, A., Kumar, K., Korde, R., Puri, S. K., Malhotra, P., Singh Chauhan, V. (2007). Falcipain-1, a Plasmodium falciparum Cysteine Protease with Vaccine Potential. Infect. Immun. 75: 2026-2034 [Abstract] [Full Text]  
  • Shi, Q., Lynch, M. M., Romero, M., Burns, J. M. Jr. (2007). Enhanced Protection against Malaria by a Chimeric Merozoite Surface Protein Vaccine. Infect. Immun. 75: 1349-1358 [Abstract] [Full Text]  
  • BONILLA, J. A., VALIDUM, L., CUMMINGS, R., PALMER, C. J. (2006). GENETIC DIVERSITY OF PLASMODIUM VIVAX PVCSP AND PVMSP1 IN GUYANA, SOUTH AMERICA. Am J Trop Med Hyg 75: 830-835 [Abstract] [Full Text]  
  • Singh, S., Miura, K., Zhou, H., Muratova, O., Keegan, B., Miles, A., Martin, L. B., Saul, A. J., Miller, L. H., Long, C. A. (2006). Immunity to Recombinant Plasmodium falciparum Merozoite Surface Protein 1 (MSP1): Protection in Aotus nancymai Monkeys Strongly Correlates with Anti-MSP1 Antibody Titer and In Vitro Parasite-Inhibitory Activity.. Infect. Immun. 74: 4573-4580 [Abstract] [Full Text]  
  • Darko, C. A., Angov, E., Collins, W. E., Bergmann-Leitner, E. S., Girouard, A. S., Hitt, S. L., McBride, J. S., Diggs, C. L., Holder, A. A., Long, C. A., Barnwell, J. W., Lyon, J. A. (2005). The Clinical-Grade 42-Kilodalton Fragment of Merozoite Surface Protein 1 of Plasmodium falciparum Strain FVO Expressed in Escherichia coli Protects Aotus nancymai against Challenge with Homologous Erythrocytic-Stage Parasites. Infect. Immun. 73: 287-297 [Abstract] [Full Text]  
  • Sachdeva, S., Ahmad, G., Malhotra, P., Mukherjee, P., Chauhan, V. S. (2004). Comparison of Immunogenicities of Recombinant Plasmodium vivax Merozoite Surface Protein 1 19- and 42-Kilodalton Fragments Expressed in Escherichia coli. Infect. Immun. 72: 5775-5782 [Abstract] [Full Text]  
  • Corran, P. H., O'Donnell, R. A., Todd, J., Uthaipibull, C., Holder, A. A., Crabb, B. S., Riley, E. M. (2004). The Fine Specificity, but Not the Invasion Inhibitory Activity, of 19-Kilodalton Merozoite Surface Protein 1-Specific Antibodies Is Associated with Resistance to Malarial Parasitemia in a Cross-Sectional Survey in The Gambia. Infect. Immun. 72: 6185-6189 [Abstract] [Full Text]  
  • John, C. C., O'Donnell, R. A., Sumba, P. O., Moormann, A. M., de Koning-Ward, T. F., King, C. L., Kazura, J. W., Crabb, B. S. (2004). Evidence That Invasion-Inhibitory Antibodies Specific for the 19-kDa Fragment of Merozoite Surface Protein-1 (MSP-119) Can Play a Protective Role against Blood-Stage Plasmodium falciparum Infection in Individuals in a Malaria Endemic Area of Africa. J. Immunol. 173: 666-672 [Abstract] [Full Text]  
  • Drew, D. R., O'Donnell, R. A., Smith, B. J., Crabb, B. S. (2004). A Common Cross-species Function for the Double Epidermal Growth Factor-like Modules of the Highly Divergent Plasmodium Surface Proteins MSP-1 and MSP-8. J. Biol. Chem. 279: 20147-20153 [Abstract] [Full Text]  
  • Singh, S., Kennedy, M. C., Long, C. A., Saul, A. J., Miller, L. H., Stowers, A. W. (2003). Biochemical and Immunological Characterization of Bacterially Expressed and Refolded Plasmodium falciparum 42-Kilodalton C-Terminal Merozoite Surface Protein 1. Infect. Immun. 71: 6766-6774 [Abstract] [Full Text]  
  • Stowers, A. W., Kennedy, M. C., Keegan, B. P., Saul, A., Long, C. A., Miller, L. H. (2002). Vaccination of Monkeys with Recombinant Plasmodium falciparum Apical Membrane Antigen 1 Confers Protection against Blood-Stage Malaria. Infect. Immun. 70: 6961-6967 [Abstract] [Full Text]  
  • Pang, A. L. Y., Hashimoto, C. N., Tam, L. Q., Meng, Z. Q., Hui, G. S. N., Ho, W. K. K. (2002). In Vivo Expression and Immunological Studies of the 42-Kilodalton Carboxyl-Terminal Processing Fragment of Plasmodium falciparum Merozoite Surface Protein 1 in the Baculovirus-Silkworm System. Infect. Immun. 70: 2772-2779 [Abstract] [Full Text]  
  • Ahlborg, N., Ling, I. T., Howard, W., Holder, A. A., Riley, E. M. (2002). Protective Immune Responses to the 42-Kilodalton (kDa) Region of Plasmodium yoelii Merozoite Surface Protein 1 Are Induced by the C-Terminal 19-kDa Region but Not by the Adjacent 33-kDa Region. Infect. Immun. 70: 820-825 [Abstract] [Full Text]  
  • King, C. L., Malhotra, I., Wamachi, A., Kioko, J., Mungai, P., Wahab, S. A., Koech, D., Zimmerman, P., Ouma, J., Kazura, J. W. (2002). Acquired Immune Responses to Plasmodium falciparum Merozoite Surface Protein-1 in the Human Fetus. J. Immunol. 168: 356-364 [Abstract] [Full Text]  
  • Saul, A., Miller, L. H. (2001). A Robust Neutralization Test for Plasmodium falciparum Malaria. JEM 193: F51-F54 [Full Text]  
  • Stowers, A. W., Chen, L.-h., Zhang, Y., Kennedy, M. C., Zou, L., Lambert, L., Rice, T. J., Kaslow, D. C., Saul, A., Long, C. A., Meade, H., Miller, L. H. (2002). A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 99: 339-344 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»